Evaluation and follow-up strategies for superficial bladder cancer

被引:87
作者
Donat, SM
机构
[1] Cornell Univ, Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA
[2] Cornell Univ, Weill Med Coll, New York, NY 10021 USA
关键词
D O I
10.1016/S0094-0143(03)00060-0
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Superficial bladder cancer comprises about 80% of patients presenting with bladder cancer to the practicing urologist. The risk of tumor recurrence is dependent on tumor stage, tumor grade, number of tumors (multifocality), the presence of associated carcinoma in situ, and the initial response to therapy. Clinical staging and completeness of resection of the primary tumor are essential in treatment planning, predicting the risk and site of recurrent disease, and determining follow-up strategies. The increasing frequency of extra-vesical recurrences over time requires continued observation of the upper tracts and prostatic urethra. Due to the panurothelial nature of the disease and lifelong risk of recurrence, surveillance should continue for the lifetime of the patient.
引用
收藏
页码:765 / +
页数:13
相关论文
共 92 条
[1]   A PROSPECTIVE RANDOMIZED TRIAL OF MAINTENANCE VERSUS NONMAINTENANCE INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY OF SUPERFICIAL BLADDER-CANCER [J].
BADALAMENT, RA ;
HERR, HW ;
WONG, GY ;
GNECCO, C ;
PINSKY, CM ;
WHITMORE, WF ;
FAIR, WR ;
OETTGEN, HF .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (03) :441-449
[2]   BCG (Bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer [J].
Bassi, PF .
SURGICAL ONCOLOGY-OXFORD, 2002, 11 (1-2) :77-83
[3]   Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin [J].
Brake, M ;
Loertzer, H ;
Horsch, R ;
Keller, H .
JOURNAL OF UROLOGY, 2000, 163 (06) :1697-1701
[4]   Second resection and prognosis of primary high risk superficial bladder cancer: Is cystectomy often too early? [J].
Brauers, A ;
Buettner, R ;
Jakse, G .
JOURNAL OF UROLOGY, 2001, 165 (03) :808-810
[5]   THE USE OF BACILLUS CALMETTE-GUERIN IN THE THERAPY OF BLADDER-CARCINOMA INSITU [J].
BROSMAN, SA .
JOURNAL OF UROLOGY, 1985, 134 (01) :36-39
[6]  
BUI TT, 1998, J UROLOGY, V159, P1770
[7]   RISKS AND BENEFITS OF REPEATED COURSES OF INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY FOR SUPERFICIAL BLADDER-CANCER [J].
CATALONA, WJ ;
HUDSON, MA ;
GILLEN, DP ;
ANDRIOLE, GL ;
RATLIFF, TL .
JOURNAL OF UROLOGY, 1987, 137 (02) :220-224
[8]   The treated natural history of high risk superficial bladder cancer: 15-year outcome [J].
Cookson, MS ;
Herr, HW ;
Zhang, ZF ;
Soloway, S ;
Sogani, PC ;
Fair, WR .
JOURNAL OF UROLOGY, 1997, 158 (01) :62-67
[9]   MANAGEMENT OF STAGE-T1 SUPERFICIAL BLADDER-CANCER WITH INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY [J].
COOKSON, MS ;
SAROSDY, MF .
JOURNAL OF UROLOGY, 1992, 148 (03) :797-801
[10]   Genetic and molecular markers of urothelial premalignancy and malignancy [J].
Cordon-Cardo, C ;
Cote, RJ ;
Sauter, G .
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2000, 34 :82-93